PLAQUE CLAIMS ARE DRUG CLAIMS
This article was originally published in The Tan Sheet
Executive Summary
PLAQUE CLAIMS ARE DRUG CLAIMS, FDA's OTC Plaque Subcommittee decided in a 4-2 vote on Dec. 7. The recommendation voted on by the subcommittee states that in classifying OTC plaque products, "all references to the control of dental plaque, or its equivalents, with or without qualification, will be interpreted as a drug claim."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning